Moderator | Percentage responders | Lower limit | Upper limit | Q-value for subgroup differences | P-value for subgroup differences |
---|---|---|---|---|---|
Antidepressant subgroups | |||||
 SSRI (N = 28) | 0.48 | 0.42 | 0.54 |  | |
 TCA (N = 15) | 0.57 | 0.50 | 0.63 | ||
 SSNRI (N = 9) | 0.49 | 0.37 | 0.61 | ||
 α2-Antagonist (N = 6) | 0.51 | 0.41 | 0.60 | ||
 SNRI (N = 2) | 0.34 | 0.09 | 0.74 | ||
 MAO-Inhibitor (N = 1) | 0.75 | 0.52 | 0.89 | ||
Setting In/ Outpatients | |||||
 Inpatients (N = 9) | 0.46 | 0.35 | 0.57 | 0.39 | 0.53 |
 Outpatients (N = 37) | 0.50 | 0.44 | 0.55 | ||
Sponsorship | |||||
 Sponsor stated (N = 39) | 0.51 | 0.46 | 0.57 | 0.10 | 0.75 |
 No sponsor stated (N = 29) | 0.50 | 0.45 | 0.55 | ||
Presence of a placebo arm | |||||
 Placebo comparison (N = 15) | 0.43 | 0.37 | 0.50 | 6.35 | 0.01 |
 No Placebo comparison (N = 53) | 0.53 | 0.49 | 0.57 | ||
Overall high risk of bias | |||||
 Studies without overall high risk of bias (N = 65) | 0.51 | 0.47 | 0.55 | 0.19 | 0.67 |
 Studies with overall high risk of bias (N = 3) | 0.44 | 0.18 | 0.74 | ||
Data analysis | |||||
 ITT (N = 53) | 0.53 | 0.49 | 0.57 | 1.22 | 0.27 |
 Completer analyses (N = 5) | 0.40 | 0.21 | 0.63 |